Jump to content
 







Main menu
   


Navigation  



Main page
Contents
Current events
Random article
About Wikipedia
Contact us
Donate
 




Contribute  



Help
Learn to edit
Community portal
Recent changes
Upload file
 








Search  

































Create account

Log in
 









Create account
 Log in
 




Pages for logged out editors learn more  



Contributions
Talk
 



















Contents

   



(Top)
 


1 Function  





2 Structure  





3 Clinical significance  





4 See also  





5 References  





6 Further reading  





7 External links  














MASP1 (protein)






Українська

 

Edit links
 









Article
Talk
 

















Read
Edit
View history
 








Tools
   


Actions  



Read
Edit
View history
 




General  



What links here
Related changes
Upload file
Special pages
Permanent link
Page information
Cite this page
Get shortened URL
Download QR code
Wikidata item
 




Print/export  



Download as PDF
Printable version
 
















Appearance
   

 






From Wikipedia, the free encyclopedia
 


MASP1
Available structures
PDBOrtholog search: PDBe RCSB
Identifiers
AliasesMASP1, 3MC1, CRARF, CRARF1, MAP1, MASP, MASP3, MAp44, PRSS5, RaRF, mannan binding lectin serine peptidase 1, Mannan-binding lectin serine protease 1, MBL associated serine protease 1, MASP-3, MAP-1
External IDsOMIM: 600521; MGI: 88492; HomoloGene: 89143; GeneCards: MASP1; OMA:MASP1 - orthologs
Orthologs
SpeciesHumanMouse
Entrez
Ensembl
UniProt
RefSeq (mRNA)

NM_001031849
NM_001879
NM_139125

NM_008555
NM_001359083

RefSeq (protein)

NP_001027019
NP_001870
NP_624302

NP_032581
NP_001346012

Location (UCSC)Chr 3: 187.22 – 187.29 MbChr 16: 23.27 – 23.34 Mb
PubMed search[3][4]
Wikidata
View/Edit HumanView/Edit Mouse

Mannan-binding lectin serine protease 1 also known as mannose-associated serine protease 1 (MASP-1) is an enzyme that in humans is encoded by the MASP1 gene.[5][6][7]

MASP-1 is involved in the lectin pathway of the complement system and is responsible for activating MASP-2 and MASP-3.[8] It is also involved in the process of cleaving complement proteins, C4 and C2, into fragments to form a C3-convertase.[9]

Function[edit]

MASP-1 is a serine protease that functions as a component of the lectin pathway of complement activation. The complement pathway plays an essential role in the innate and adaptive immune response as it allows the body to clear foreign material.[10] MASP-1 is synthesized as a zymogen and is activated when it creates a complex of proteins with the pathogen recognition molecules oft the lectin pathway: the mannose-binding lectin and the ficolins. This protein is directly involved in complement activation because MASP-1 activates MASP-2 by cleaving (cutting off a piece) a MASP-2 zymogen.[11] MASP-2 is then able to cleave C4 into proteins C4a and C4b. MASP-1 is also responsible for creating C3 convertase by cleaving C2 into C2b and C2a. C2a and C4b are used to create C3 convertase, a complex that will then be able to cleave C3 into C3a and C3b. However, MASP-1 is useful for biological pathways other than the complement pathway, such as blood clots. MASP-1 can cleave coagulation pathway proteins such as PAR-4, fibrinogen, and factor XIII which leads to high clot and fibrin generation.[12][11] A spliced variant of this gene, which lacks the serine protease domain, functions as an inhibitor of the complement pathway.[7]

Structure[edit]

MASP-1’s structure is similar to other MASP proteins. The MASP1 gene encodes MASP-1 as well as MASP-3 (via alternative splicing).[13] Despite being made from different genes and spliced genes, all MASP proteins have the same structure of a heavy/alpha chain, a light/beta chain, and an interconnecting cysteine disulfide bond. The heavy chain is made up of two CUB domains and two complement control protein (CCP) domains that are connected by an epidermal growth factor segment (EGF). However, the full crystal structure of MASP proteins has not yet been formulated.[14]

Clinical significance[edit]

MASP1 gene changes can lead to several diseases in patients due to subsequent MASP-1 protein changes. MASP1 gene changes (polymorphisms) can lead to systemic inflammatory response syndrome (SIRS)/sepsis, malpuech facial clefting (3MC) syndrome, and bacterial colonization in those with cystic fibrosis. Also, MASP-1 is essential for stem cell transplantation as it is involved in the transportation of bone marrow stem cells to the blood.[15] Furthermore, single-nucleotide polymorphisms (SNPs) in MASP1 genes can lead to impaired blood clotting and complement activation.[16] Overproduction of MASP-1 proteins can also be related to some diseases. For example, cardiovascular diseases increase MASP-1 levels, especially in cases such as subacute myocardial infarction. MASP-1 is also upregulated in patients with uterine leiomyosarcoma, and it can potentially activate the alternative pathway of complement in inflammatory arthritis patients. Hepatitis C (HCV), a liver disease, is associated with MASP-1 due to the localization of high concentrations of MASP-1 in infected livers. Higher levels of MASP-1 correlated with severe HCV-related liver fibrosis.[16]

See also[edit]

References[edit]

  • ^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  • ^ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  • ^ Takada F, Takayama Y, Hatsuse H, Kawakami M (October 1993). "A new member of the C1s family of complement proteins found in a bactericidal factor, Ra-reactive factor, in human serum". Biochemical and Biophysical Research Communications. 196 (2): 1003–1009. doi:10.1006/bbrc.1993.2349. PMID 8240317.
  • ^ Sato T, Endo Y, Matsushita M, Fujita T (April 1994). "Molecular characterization of a novel serine protease involved in activation of the complement system by mannose-binding protein". International Immunology. 6 (4): 665–669. doi:10.1093/intimm/6.4.665. PMID 8018603.
  • ^ a b "Entrez Gene: mannan-binding lectin serine peptidase 1 (C4/C2 activating component of Ra-reactive factor)".
  • ^ Sekine H, Takahashi M, Iwaki D, Fujita T (2013). "The Role of MASP-1/3 in Complement Activation". In Lambris JD, Holers VM, Ricklin D (eds.). Complement Therapeutics. Advances in Experimental Medicine and Biology. Vol. 735. New York, NY: Springer US. pp. 41–53. doi:10.1007/978-1-4614-4118-2_3. ISBN 978-1-4614-4118-2. PMID 23402018.
  • ^ Matsushita M, Thiel S, Jensenius JC, Terai I, Fujita T (September 2000). "Proteolytic activities of two types of mannose-binding lectin-associated serine protease". Journal of Immunology. 165 (5): 2637–2642. doi:10.4049/jimmunol.165.5.2637. PMID 10946292.
  • ^ Atik T, Koparir A, Bademci G, Foster J, Altunoglu U, Mutlu GY, et al. (September 2015). "Serine Proteases in the Lectin Pathway of the Complement System". Proteases in Physiology and Pathology. Vol. 10. pp. 397–420. doi:10.1007/978-981-10-2513-6_18. ISBN 978-981-10-2512-9. PMC 7120406. PMID 26419238. {{cite book}}: |journal= ignored (help)
  • ^ a b Dobó J, Schroeder V, Jenny L, Cervenak L, Závodszky P, Gál P (October 2014). "Multiple roles of complement MASP-1 at the interface of innate immune response and coagulation" (PDF). Molecular Immunology. XXV International Complement Workshop September 14-18, 2014 - Rio de Janeiro, Brazil. 61 (2): 69–78. doi:10.1016/j.molimm.2014.05.013. PMID 24935208.
  • ^ Kjaer TR, Thiel S, Andersen GR (December 2013). "Toward a structure-based comprehension of the lectin pathway of complement" (PDF). Molecular Immunology. 56 (4): 413–422. doi:10.1016/j.molimm.2013.05.007. PMID 23911397.
  • ^ Takahashi M, Mori S, Shigeta S, Fujita T (2007). "Role of MBL-associated Serine Protease (MASP) on Activation of the Lectin Complement Pathway". In Lambris JD (ed.). Current Topics in Innate Immunity. Advances in Experimental Medicine and Biology. Vol. 598. Springer. pp. 93–104. doi:10.1007/978-0-387-71767-8_8. ISBN 978-0-387-71767-8. PMID 17892207.
  • ^ Garred P, Genster N, Pilely K, Bayarri-Olmos R, Rosbjerg A, Ma YJ, Skjoedt MO (November 2016). "A journey through the lectin pathway of complement-MBL and beyond". Immunological Reviews. 274 (1): 74–97. doi:10.1111/imr.12468. PMID 27782323. S2CID 37084404.
  • ^ Cedzyński M, Świerzko AS (July 2020). "Components of the Lectin Pathway of Complement in Haematologic Malignancies". Cancers. 12 (7): 1792. doi:10.3390/cancers12071792. PMC 7408476. PMID 32635486.
  • ^ a b Beltrame MH, Boldt AB, Catarino SJ, Mendes HC, Boschmann SE, Goeldner I, Messias-Reason I (September 2015). "MBL-associated serine proteases (MASPs) and infectious diseases". Molecular Immunology. 15th European Meeting on Complement in Human Disease 2015, Uppsala, Sweden. 67 (1): 85–100. doi:10.1016/j.molimm.2015.03.245. PMC 7112674. PMID 25862418.
  • Further reading[edit]

  • Petersen SV, Thiel S, Jensenius JC (August 2001). "The mannan-binding lectin pathway of complement activation: biology and disease association". Molecular Immunology. 38 (2–3): 133–149. doi:10.1016/S0161-5890(01)00038-4. PMID 11532276.
  • Rajaraman P, Brenner AV, Butler MA, Wang SS, Pfeiffer RM, Ruder AM, et al. (May 2009). "Common variation in genes related to innate immunity and risk of adult glioma". Cancer Epidemiology, Biomarkers & Prevention. 18 (5): 1651–1658. doi:10.1158/1055-9965.EPI-08-1041. PMC 2771723. PMID 19423540.
  • Dobó J, Harmat V, Beinrohr L, Sebestyén E, Závodszky P, Gál P (July 2009). "MASP-1, a promiscuous complement protease: structure of its catalytic region reveals the basis of its broad specificity". Journal of Immunology. 183 (2): 1207–1214. doi:10.4049/jimmunol.0901141. PMID 19564340.
  • Skjoedt MO, Hummelshoj T, Palarasah Y, Honore C, Koch C, Skjodt K, Garred P (March 2010). "A novel mannose-binding lectin/ficolin-associated protein is highly expressed in heart and skeletal muscle tissues and inhibits complement activation". The Journal of Biological Chemistry. 285 (11): 8234–8243. doi:10.1074/jbc.M109.065805. PMC 2832975. PMID 20053996.
  • Han S, Lan Q, Park AK, Lee KM, Park SK, Ahn HS, et al. (July 2010). "Polymorphisms in innate immunity genes and risk of childhood leukemia". Human Immunology. 71 (7): 727–730. doi:10.1016/j.humimm.2010.04.004. PMC 2967770. PMID 20438785.
  • Kocsis A, Kékesi KA, Szász R, Végh BM, Balczer J, Dobó J, et al. (October 2010). "Selective inhibition of the lectin pathway of complement with phage display selected peptides against mannose-binding lectin-associated serine protease (MASP)-1 and -2: significant contribution of MASP-1 to lectin pathway activation". Journal of Immunology. 185 (7): 4169–4178. doi:10.4049/jimmunol.1001819. hdl:10831/91219. PMID 20817870.
  • Rooryck C, Diaz-Font A, Osborn DP, Chabchoub E, Hernandez-Hernandez V, Shamseldin H, et al. (March 2011). "Mutations in lectin complement pathway genes COLEC11 and MASP1 cause 3MC syndrome". Nature Genetics. 43 (3): 197–203. doi:10.1038/ng.757. PMC 3045628. PMID 21258343.
  • Megyeri M, Makó V, Beinrohr L, Doleschall Z, Prohászka Z, Cervenak L, et al. (September 2009). "Complement protease MASP-1 activates human endothelial cells: PAR4 activation is a link between complement and endothelial function". Journal of Immunology. 183 (5): 3409–3416. doi:10.4049/jimmunol.0900879. PMID 19667088.
  • Sirmaci A, Walsh T, Akay H, Spiliopoulos M, Sakalar YB, Hasanefendioğlu-Bayrak A, et al. (November 2010). "MASP1 mutations in patients with facial, umbilical, coccygeal, and auditory findings of Carnevale, Malpuech, OSA, and Michels syndromes". American Journal of Human Genetics. 87 (5): 679–686. doi:10.1016/j.ajhg.2010.09.018. PMC 2978960. PMID 21035106.
  • Hosgood HD, Menashe I, He X, Chanock S, Lan Q (December 2009). "PTEN identified as important risk factor of chronic obstructive pulmonary disease". Respiratory Medicine. 103 (12): 1866–1870. doi:10.1016/j.rmed.2009.06.016. PMC 2783799. PMID 19625176.
  • Hosgood HD, Menashe I, Shen M, Yeager M, Yuenger J, Rajaraman P, et al. (October 2008). "Pathway-based evaluation of 380 candidate genes and lung cancer susceptibility suggests the importance of the cell cycle pathway". Carcinogenesis. 29 (10): 1938–1943. doi:10.1093/carcin/bgn178. PMC 2722857. PMID 18676680.
  • Kang JU, Koo SH, Kwon KC, Park JW, Kim JM (July 2009). "Identification of novel candidate target genes, including EPHB3, MASP1 and SST at 3q26.2-q29 in squamous cell carcinoma of the lung". BMC Cancer. 9: 237. doi:10.1186/1471-2407-9-237. PMC 2716371. PMID 19607727.
  • Skjoedt MO, Palarasah Y, Munthe-Fog L, Jie Ma Y, Weiss G, Skjodt K, et al. (November 2010). "MBL-associated serine protease-3 circulates in high serum concentrations predominantly in complex with Ficolin-3 and regulates Ficolin-3 mediated complement activation". Immunobiology. 215 (11): 921–931. doi:10.1016/j.imbio.2009.10.006. PMID 19939495.
  • Degn SE, Hansen AG, Steffensen R, Jacobsen C, Jensenius JC, Thiel S (December 2009). "MAp44, a human protein associated with pattern recognition molecules of the complement system and regulating the lectin pathway of complement activation". Journal of Immunology. 183 (11): 7371–7378. doi:10.4049/jimmunol.0902388. PMID 19917686.
  • Rajaraman P, Brenner AV, Neta G, Pfeiffer R, Wang SS, Yeager M, et al. (May 2010). "Risk of meningioma and common variation in genes related to innate immunity". Cancer Epidemiology, Biomarkers & Prevention. 19 (5): 1356–1361. doi:10.1158/1055-9965.EPI-09-1151. PMC 3169167. PMID 20406964.
  • Ennis S, Jomary C, Mullins R, Cree A, Chen X, Macleod A, et al. (November 2008). "Association between the SERPING1 gene and age-related macular degeneration: a two-stage case-control study". Lancet. 372 (9652): 1828–1834. doi:10.1016/S0140-6736(08)61348-3. PMC 5983350. PMID 18842294.
  • Shen M, Vermeulen R, Rajaraman P, Menashe I, He X, Chapman RS, et al. (May 2009). "Polymorphisms in innate immunity genes and lung cancer risk in Xuanwei, China". Environmental and Molecular Mutagenesis. 50 (4): 285–290. Bibcode:2009EnvMM..50..285S. doi:10.1002/em.20452. PMC 2666781. PMID 19170196.
  • Duus K, Thielens NM, Lacroix M, Tacnet P, Frachet P, Holmskov U, Houen G (December 2010). "CD91 interacts with mannan-binding lectin (MBL) through the MBL-associated serine protease-binding site". The FEBS Journal. 277 (23): 4956–4964. doi:10.1111/j.1742-4658.2010.07901.x. PMID 21054788. S2CID 31526986.
  • Degn SE, Jensen L, Gál P, Dobó J, Holmvad SH, Jensenius JC, Thiel S (September 2010). "Biological variations of MASP-3 and MAp44, two splice products of the MASP1 gene involved in regulation of the complement system". Journal of Immunological Methods. 361 (1–2): 37–50. doi:10.1016/j.jim.2010.07.006. PMID 20673767.
  • External links[edit]

    This article incorporates text from the United States National Library of Medicine, which is in the public domain.



    Retrieved from "https://en.wikipedia.org/w/index.php?title=MASP1_(protein)&oldid=1210584241"

    Categories: 
    Genes on human chromosome 3
    Complement system
    EC 3.4.21
    Hidden categories: 
    CS1 errors: periodical ignored
    Articles with short description
    Short description matches Wikidata
    Wikipedia articles incorporating text from the United States National Library of Medicine
     



    This page was last edited on 27 February 2024, at 09:47 (UTC).

    Text is available under the Creative Commons Attribution-ShareAlike License 4.0; additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy. Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc., a non-profit organization.



    Privacy policy

    About Wikipedia

    Disclaimers

    Contact Wikipedia

    Code of Conduct

    Developers

    Statistics

    Cookie statement

    Mobile view



    Wikimedia Foundation
    Powered by MediaWiki